ChiCTR2500114027 版本V1.0 版本创建时间2025/12/05 16:04:15 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500114027 

最近更新日期:

Date of Last Refreshed on:

2025-12-05 16:04:01 

注册时间:

Date of Registration:

2025-12-05 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

男男性行为者HIV合并猴痘感染传播动力学及风险预测模型研究

Public title:

Study on the transmission dynamics and risk prediction model of HIV co-infection with monkeypox in men who have sex with men

注册题目简写:

English Acronym:

研究课题的正式科学名称:

男男性行为者HIV合并猴痘感染传播动力学及风险预测模型研究

Scientific title:

Study on the transmission dynamics and risk prediction model of HIV co-infection with monkeypox in men who have sex with men

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

吴碧容 

研究负责人:

王英 

Applicant:

Wu Birong 

Study leader:

Ying Wang 

申请注册联系人电话:

Applicant telephone:

+86 21 52039999

研究负责人电话:

Study leader's
telephone:

+86 21 52039999

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

18055965207@163.com

研究负责人电子邮件:

Study leader's E-mail:

yingwangxun@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市长宁区仙霞路1111号

研究负责人通讯地址:

上海市长宁区仙霞路1111号

Applicant address:

No. 1111, Xianxia Road, Changning District, Shanghai, China

Study leader's address:

No. 1111, Xianxia Road, Changning District, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海交通大学医学院附属同仁医院

Applicant's institution:

Tongren Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine

研究负责人所在单位:

上海市同仁医院

Affiliation of the Leader:

Shanghai Tongren Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

同仁伦审K2025-075-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海市同仁医院伦理委员会

Name of the ethic committee:

Ethics Committee of Shanghai Tongren Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-10-28 00:00:00

伦理委员会联系人:

王春燕

Contact Name of the ethic committee:

Wang Chunyan

伦理委员会联系地址:

上海市长宁区仙霞路1111号

Contact Address of the ethic committee:

No. 1111, Xianxia Road, Changning District, Shanghai, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 21 52039999

伦理委员会联系人邮箱:

Contact email of the ethic committee:

wongchy@hotmail.com

研究实施负责(组长)单位:

上海市同仁医院

Primary sponsor:

Shanghai Tongren Hospital

研究实施负责(组长)单位地址:

上海市长宁区仙霞路1111号

Primary sponsor's address:

No. 1111, Xianxia Road, Changning District, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海市

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市同仁医院

具体地址:

上海市长宁区仙霞路1111号

Institution
hospital:

Shanghai Tongren Hospital

Address:

No. 1111, Xianxia Road, Changning District, Shanghai, China

经费或物资来源:

上海市公共卫生研究专项;自选课题(自筹)

Source(s) of funding:

Public Health Research Project from Shanghai Disease Control and Prevention Administration ;Public Health Research Project from Shanghai Disease Control and Prevention Administration

研究疾病:

男男性行为者的HIV合并猴痘感染  

Target disease:

HIV and mpox co-infection among men who have sex with men (MSM)

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

基于前期收集的 2000 例样本构建 HIV 合并猴痘感染风险预测模型,本次研究拟再收集 600 例研究对象开展模型的外部验证,以检验其稳健性和泛化能力,从而实现对高风险个体的有效识别,并为制定个性化干预策略提供依据。  

Objectives of Study:

Based on the previously collected 2,000 samples used to develop a predictive model for HIV and monkeypox coinfection risk, this study will collect an additional 600 participants to conduct external validation of the model. This validation aims to assess the model’s robustness and generalizability, thereby enabling effective identification of high-risk individuals and providing evidence to support the development of personalized intervention strategies.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.男性且年满18周岁; 2.最近6个月发生过男男性行为; 3.常住于被选择的六个现场(近6月内主要时间居住于当地);

Inclusion criteria

1.Male and 18 years of age or older; 2.Has engaged in male-to-male sexual activity in the past 6 months; 3.Resides in one of the six selected locations (primarily resides locally in the past 6 months).

排除标准:

1.填写问卷时间少于300秒; 2.质控题回答错误; 3.IP显示地非该调查省市;

Exclusion criteria:

1.The questionnaire completion time is less than 300 seconds; 2. Incorrect answers to quality control questions; 3. IP address indicates a location outside the survey province or city.

研究实施时间:

Study execute time:

From 2025-01-01 00:00:00 To 2027-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-11-17 00:00:00 To 2027-12-31 00:00:00

干预措施:

Interventions:

组别:

是否HIV合并猴痘双重感染

样本量:

600

Group:

Whether men who have sex with men are infected with HlV and monkeypox

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海市 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市同仁医院 

单位级别:

三级 

Institution
hospital:

Shanghai Tongren Hospital

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

调查人群中的男男性行为者HIV合并猴痘感染比例

指标类型:

主要指标

Outcome:

Proportion of HIV and mpox co-infection among men who have sex with men (MSM) in this study population

Type:

Primary indicator

测量时间点:

2025年11月至2026年6月

测量方法:

问卷调查

Measure time point of outcome:

From November 2025 to June 2026

Measure method:

Questionnaire survey

指标中文名:

社区层面指标,包括猴痘就医歧视、猴痘感染的社会规范、猴痘疫苗的接种意愿、内部及外部奖励、反应效能和反应代价、社会支持等

指标类型:

次要指标

Outcome:

Community-level indicators, including healthcare discrimination related to monkeypox, social norms regarding monkeypox infection, willingness to receive the monkeypox vaccine, internal and external re

Type:

Secondary indicator

测量时间点:

From November 2025 to June 2026

测量方法:

问卷调查

Measure time point of outcome:

From November 2025 to June 2026

Measure method:

Questionnaire survey

指标中文名:

人口学基本信息,包括年龄、文化程度、籍贯、婚姻、收入、吸烟或饮酒情况、性取向、HIV自愿检测经历、HIV预防需求、既往性传播疾病(STD/HIV)感染状况自我报告等

指标类型:

次要指标

Outcome:

Demographic information, including age, education level, place of origin, marital status, income, smoking and drinking behaviors, sexual orientation, history of voluntary HIV testing, HIV prevention n

Type:

Secondary indicator

测量时间点:

2025年11月至2026年6月

测量方法:

问卷调查

Measure time point of outcome:

From November 2025 to June 2026

Measure method:

Questionnaire survey

指标中文名:

人际层面指标,包括无保护性行为和多性伴行为、亲密伴侣感染情况、筛查就诊的意愿和相关因素、人际关联的心理因素、感知歧视等

指标类型:

次要指标

Outcome:

Interpersonal-level indicators, including unprotected sexual behavior and multiple-partner sexual behavior, infection status of intimate partners, willingness and related factors for screening and hea

Type:

Secondary indicator

测量时间点:

2025年11月至2026年6月

测量方法:

问卷调查

Measure time point of outcome:

From November 2025 to June 2026

Measure method:

Questionnaire survey

指标中文名:

个体层面指标,包括HIV和性传播疾病的感染状态、猴痘的知识、猴痘易感性认知和风险判断、猴痘预防的自我效能、感染猴痘的个体和社会规范、猴痘的诊断史和相关临床症状、人格量表等

指标类型:

次要指标

Outcome:

Individual-level indicators, including HIV and sexually transmitted infection (STI) status, knowledge of monkeypox, perceived susceptibility and risk appraisal of monkeypox, self-efficacy for monkeypo

Type:

Secondary indicator

测量时间点:

2025年11月至2026年6月

测量方法:

问卷调查

Measure time point of outcome:

From November 2025 to June 2026

Measure method:

Questionnaire survey

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男性

Gender:

Male

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

论文发表后一年内,医学登记备案系统,https://www.medicalresearch.org.cn/。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Within one year after the paper is published, register in the Medical Registration and Filing System at https://www.medicalresearch.org.cn/.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据来源包括官方数据、临床数据库和多中心、大样本横断面研究数据。官方数据主要通过广泛查阅文献,充分利用我国中国艾滋病数据库平台以及我国疫情网络直报系统和哨点监测的数据,查阅《中国艾滋病疫情与防治工作进展》、《中国艾滋病防治联合评估报告》《中国艾滋病疫情估计工作报告》等重要文件获得。多中心数据的获取主要在政府疾控部门和非政府组织(NGO)的协助下进行。研究选取了全国六大地理分区的代表性地区,包括西北的新疆维吾尔自治区、东北的辽宁省、中西部的陕西省、西南的云南省、东南的广东省以及东部沿海的上海市作为调查现场,通过现场工作人员组织的问卷星线上调查。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The data sources include official data, clinical databases, and multicenter large-sample cross-sectional study data. Official data were primarily obtained through extensive literature review and full use of the national AIDS database platform, as well as data from China’s infectious disease reporting system and sentinel surveillance system. Key documents consulted included the China HIV/AIDS Epidemic and Prevention and Control Progress Report, the China Joint Assessment Report on HIV/AIDS Prevention and Control, and the China HIV/AIDS Epidemic Estimation Report. Multicenter data collection was conducted mainly with the support of government CDC departments and non-governmental organizations (NGOs). Representative regions were selected from six major geographic divisions of the country, including Xinjiang Uygur Autonomous Region in the Northwest, Liaoning Province in the Northeast, Shaanxi Province in the Central-West, Yunnan Province in the Southwest, Guangdong Province in the Southeast, and Shanghai Municipality along the eastern coast. Data were collected through an online survey administered via Questionnaire Star, organized by field staff at each site.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2025-12-05 16:04:01